Daniela Semedo, PhD,  —

Under a research contract award granted by the Cystic Fibrosis Foundation Therapeutics (CFFT), Matinas BioPharma and the Colorado State University (CSU) will jointly conduct preclinical studies assessing the efficacy of MAT2501, a potential oral antibiotic, in treating nontuberculous mycobacterium infection (NTM) in a cystic fibrosis (CF) lung model.

The Gregory Fleming James Cystic Fibrosis Research Center (CFRC) at the University of Alabama at Birmingham (UAB) has acquired a MILabs adaptive X-ray CT system to conduct research in animal models of lung diseases, mainly in cystic fibrosis, but also in pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), and sinonasal conditions.

Researchers at the University of Pittsburgh have been awarded with a $1.7 million grant from the National Institutes of Health (NIH) to develop better ways of evaluating, and potentially treating, cystic fibrosis (CF). Specifically, the grant will be used to develop mathematical models of liquid and ion transport in the human…

Pharmaxis has entered into a research collaboration with the Woolcock Institute of Medical Research in Sydney, Australia, to develop an inhalation therapy that combines Pharmaxis’ Orbital Inhaler with a dry powder formulation of the antibiotic tobramycin. The resulting therapy is intended for patients with cystic fibrosis (CF).

Celtaxsys recently announced that a second study describing the results of Phase 1 clinical trials evaluating acebilustat, an oral treatment for cystic fibrosis (CF), has been published. A Phase 2 study is underway and currently enrolling patients in the U.S., Canada and Europe. The research article is titled “Phase 1…

ProQR Therapeutics is reporting that an early clinical study of  QR-010 in cystic fibrosis patients homozygous for the ΔF508 mutation in the CFTR gene met its primary endpoint. After four weeks of treatment, these patients showed a positive change in total chloride response, meaning that the CFTR protein was again working. In patients heterozygous for…

TGV-inhalonix reported  that its therapeutic agent Mul-1867  is continuing to show promise in treating antibiotic-resistant lung infections — namely, mixed bacterial and fungal infections — in patients with cystic fibrosis (CF), and it is planning to bring the treatment into clinical testing in the U.S. within two years. Data…

Catabasis Pharmaceuticals announced that it will present data on CAT-5571, its investigational oral treatment for cystic fibrosis (CF). The drug has potential effectiveness both on improving the working of the cystic fibrosis transmembrane conductance regulator (CFTR), and in treating Pseudomonas aeruginosa infection. The data will be presented at the 30th Annual North American Cystic Fibrosis…

The National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has granted a five-year, $13.3 million award to Benjamin Gaston, MD, to lead a research program aimed at translating new, small molecule drugs into personalized combination therapies for children with severe asthma and cystic fibrosis (CF). The…

Aradigm Corporation and the Woolcock Institute are collaborating to develop cutting-edge nanotechnologies that target the bacterial and fungal biofilms often present in patients with cystic fibrosis (CF), non-CF bronchiectasis (non-CF BE), and other chronic lung diseases. The most prevalent pathogenic microorganisms found in CF and non-CF BE patients are Haemophilus influenzae, Pseudomonas aeruginosa,…